Cerebrospinal fluid circulating tumor DNA profiling in central nervous system metastases from solid tumors: A prospective multicentre translational analysis of the BrainStorm (OncoDistinct-006) study
Spinal fluid testing can safely reveal brain cancer's genetic changes, offering a less invasive way to guide treatment decisions.
BACKGROUND: Central nervous system (CNS) metastases represent a complication in solid tumors and often harbour unique genomic alterations diverging from those in primary tumor tissue or plasma; however, direct sampling of CNS lesions carries procedural risks, limiting its molecular profiling. CONCLUSIONS: These preliminary findings indicate that CSF ctDNA can provide a sensitive, compartment-specific molecular portrait of CNS disease, complementing plasma-based analyses, and supporting its integration as a minimally invasive tool to capture the evolving genomic landscape of CNS metastases.
What the study was
- Study design
- Observational/Cohort Study
- Population
- BACKGROUND: Central nervous system (CNS) metastases represent a complication in solid tumors and oft
- Sample size
- 11
- Category
- Early Detection
- Maturity
- Validated
- Journal
- The journal of liquid biopsy
Why it surfaced
Primary method is liquid biopsy/ctDNA/cfDNA for cancer detection; moderate relevance to watchlist
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.